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Abstract
Background: With 2.5 million new HIV infections per year, effective preventive methods against
HIV are urgently needed, especially in sub-Saharan Africa. MDP301 is an ongoing trial of the vaginal
microbicide PRO 2000/5 being conducted by the Microbicides Development Programme. The main
objective of the trial is to determine the efficacy and safety of 0.5% and 2% concentrations of PRO
2000/5 gel compared to placebo in preventing vaginally acquired HIV infection.
Methods/Design: MDP301 is a multicentre randomised placebo-controlled Phase III trial. The
design was informed by pre-trial feasibility and pilot studies. The choice of trial population,
assessments and endpoints are discussed along with statistical and ethical considerations.
Adaptations to the design were made during the conduct of the trial; these included closing a study
arm and changing the timing of the primary endpoint.
Discussion: The development of effective microbicide products remains one of the strongest
hopes for new biomedical prevention tools. MDP301 is the largest Phase III microbicide trial to
date, with 9404 enrolments, and is scheduled for completion in September 2009. Results are
expected towards the end of 2009.
Trial registration: Current controlled trials ISRCTN64716212.
Background
The global pandemic of HIV infection continues to be one
of the world's most pressing public health problems. After
25 years there is still little progress in reducing the spread
of the epidemic which has had such widespread social and
economic effects on poor communities in developing
countries particularly in sub-Saharan Africa. With an esti-
mated 2.5 million new infections in 2007[1], there is an
urgent need for effective prevention measures.
In the face of such high prevalence and incidence, it is
likely that a range of complementary interventions will be
needed to bring HIV epidemics under more effective con-
trol. Thus, while behavioural modification and male cir-
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cumcision [2-5] have an important role to play, other
prevention measures need to be developed and tested. It
is unlikely that an effective HIV vaccine will be available
within the next ten years. The male condom represents the
best available barrier method of protection, and is highly
effective if used correctly and consistently. Unfortunately,
regular condom use is particularly difficult to achieve
among married couples or others in long-term relation-
ships, and is clearly inappropriate for couples wishing to
have children. An effective vaginal microbicide could offer
the possibility of providing protection in such circum-
stances.
The results of the COL-1492 trial evaluating the effective-
ness and safety of Nonoxynol-9 (N9), a licensed spermi-
cide, in the prevention of vaginally acquired HIV infection
in commercial sex workers, confirmed that development
of a topically applied agent to prevent HIV was going to be
challenging[6]. The increased risk of HIV in women using
N9, and correlation between frequent use of N9 and gen-
ital ulceration, informed the need for a wide therapeutic
index in vitro and absence of genital toxicity in Phase I/II
trials when selecting future candidates. More recent
microbicide trial results, although disappointing, have
not, like N9, demonstrated an obvious harmful microbi-
cide effect [7-10]. Although the Cellulose Sulphate trial
was stopped prematurely for harm based on an interim
result, the final reported results did not show significant
evidence of harm[8].
At the time when the N9 results were released (June
2000), five research groups were planning programmes of
research to evaluate six candidate microbicides. One of
these candidates was PRO 2000/5, a naphthalene sulpho-
nate polymer which disrupts the attachment and fusion
steps in HIV infection of target cells. In this paper, we
describe the rationale and design of an ongoing multi-
centre Phase III trial of PRO 2000/5 which is being carried
out by the Microbicides Development Programme. This is
the largest Phase III microbicide trial to date, with 9404
enrolments, and is scheduled for completion in August
2009. We also discuss adaptations to the design that have
been made during the conduct of the trial.
The main objective of the trial, designated MDP301, is to
determine the efficacy and safety of 0.5% and 2% concen-
trations of PRO 2000/5 gel compared to placebo in pre-
venting vaginally acquired HIV infection.
Methods/Design
Study populations
The trial is being carried out in six study locations in East-
ern and Southern Africa, each coordinated by an academic
institution or collaboration that is a partner in MDP. Each
location has a single data management centre responsible
for one or more clinic sites. Multiple research clinics were
needed to provide an adequate sample size for the study
in a timely manner, but also have the advantage of pro-
ducing results which should be of greater generalisability.
The six study locations are shown in Figure 1 (map) and
the populations are described in the Appendix. These pop-
ulations were selected because they were known to be at
moderate-to-high risk of HIV infection and because HIV
incidence was expected to be sufficiently high to meet the
sample size requirements of the trial. Prior to the trial,
Feasibility Studies were carried out by each of the partners
to confirm this and to inform sample size calculations.
The three South African partners recruited HIV-uninfected
women initially from health centres and family planning
clinics but then through word of mouth and community
hotspots in poor urban settlements close to Johannesburg
and Durban, and from a rural population in KwaZulu
Natal that forms part of a demographic surveillance sys-
tem. These study populations are considered to be
broadly representative of women at risk in the general
population in these areas. The Zambian site recruited
women who were provided with health care through their
employment, or their partner's employment, on a sugar
estate near the town of Mazabuka, as well as women in
Mazabuka.
HIV prevalence at the remaining two sites in Tanzania and
Uganda is known to be lower in the general population
than in the four sites described above[1] and so women
were recruited from two populations at increased risk. In
Mwanza City, Tanzania, the trial recruited women who
work in food and recreational facilities, including local
food stalls, bars, guesthouses and brew shops. These occu-
pational groups are known to be at high risk of HIV and
other sexually transmitted infections (STIs) because some
of the women supplement their incomes through occa-
sional transactional sex. Finally, in Masaka, Uganda, the
trial recruited women who are in discordant partnerships,
that is their husband or regular male partner is known to
be HIV-positive. In order to preserve the confidentiality of
the male partners, a small proportion of sero-concordant
negative couples were also included.
In COL-1492, and previous microbicide trials, the study
populations targeted were commercial sex workers. Due
to the concern that toxicity may have occurred because of
a very high frequency of sexual acts and therefore excessive
use of the microbicide product, it was decided to target
women who were less sexually active.
Taking this into consideration the eligibility criteria for
the trial were as follows.
Inclusion
 Women aged 16 years and above at enrolment in
Masaka and Mwanza, or aged 18 years and above at enrol-
ment in the South African and Zambian sitesTrials 2009, 10:99 http://www.trialsjournal.com/content/10/1/99
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 Likely to be sexually active at entry and during follow-
up
 Willing to undergo HIV testing at screening and approx-
imately 12 weekly intervals, and additionally if required
to determine HIV status
 HIV negative at screening according to the local HIV
testing algorithm
 Willing to receive the HIV result before randomisation
 Willing to use study gel as instructed
 Willing to undergo regular speculum examinations and
genital infection screens
 Willing to have regular urine pregnancy tests
 Willing to receive health education about condoms
 Willing and able to give informed consent
Exclusion
 Unable or unwilling to provide a reliable method of
contact for the field team
 Likely to move permanently out of the area within the
next year
 Likely to have sex more than 14 times a week on a reg-
ular basis during the course of follow-up
 Using spermicides regularly
 Pregnant or within 6 weeks postpartum at enrolment
 Has grade 3 clinical or laboratory abnormalities which
are considered by the clinician or the Trial Management
Group to make enrolment inadvisable
 Requiring referral for assessment of a clinically suspi-
cious cervical lesion
Map of MDP301 clinical trial sites in Africa Figure 1
Map of MDP301 clinical trial sites in Africa.
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 Treatment to the cervix, or to the womb through the
cervix, within 30 days of enrolment
 Known latex allergy
 Participating, or having participated within 30 days of
enrolment, in a clinical trial of an unlicensed product,
microbicide, barrier method or any other intervention
likely to impact on the outcome of this trial
 Considered unlikely to be able to comply with the pro-
tocol
Feasibility and pilot studies
Feasibility Studies were carried out at the trial sites before
the trial commenced to measure HIV incidence, preg-
nancy and retention rates and to evaluate behavioural
characteristics and condom use in women from the pro-
posed study populations in a context of risk reduction
counselling and condom promotion. Some of the key
findings from the Feasibility Studies are summarised in
Table 1. These data informed the sample size assumptions
for MDP301, both in terms of the estimate of the HIV inci-
dence in the control arm and retention of participants.
Among 3174 women enrolled in these studies, there were
120 subsequent incident cases of HIV infection corre-
sponding to incidence rates which ranged from 3.5 to
12.6 per 100 woman-years of observation across the sites.
The weighted estimate of HIV incidence, adjusting for the
proportion of participants each site was expected to be
able to contribute to the trial, was 6.2 per 100 woman-
years. We decided to use a conservative estimate of 4 per
100 women years for HIV incidence in the control arm as
we thought it possible that women that correctly identi-
Table 1: Feasibility Study data.
South Africa Zambia Tanzania Uganda
Durban Joburg Africa Centre sites Mazabuka Mwanza+ Masaka*
Populations Health clinics and associated communities Recreational facilities Sero-discordant couples
Start date Aug 02 Oct 02 Jul 03 Mar03 Mar 03 Oct 03
N screened 1263 1088 882 1974 1573 1370
% HIV +ve at screen 47% 20% 50% 30% 25% 7%
% pregnant at screen 1% 4% 1% 4% 10% -
N enrolled 608 757 453 590 1573 50
% of enrolled seen at FU or later†
3 m 94% 84% 63% 87% 83% 90%
6 m 88% 79% 56% 79% 79% 84%
9 m 82% 83% 56% 70% 70% 86%
12 m 67% 87% 58% 63% 71% 86%
Recruitment period (months) 14 15 12 18 14 2
Person years FU 499.2 531.4 158.1 356.4 717.4 31.2
Sero-conversions 37 21 20 13 25 4
HIV incidence 7.4 3.9 12.6 3.6 3.5 12.6
95%CI 5.4, 10.2 2.6, 6.1 8.2, 19.6 2.1, 6.3 2.4, 5.2 4.8, 34.1
†follow-up rates based on % of 3 month attendees who returned subsequently; +All 1573 women were enrolled in Mwanza but the HIV incidence 
calculation was based on those who were HIV negative at enrolment;*sero-discordant couples enrolledTrials 2009, 10:99 http://www.trialsjournal.com/content/10/1/99
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fied themselves at high risk may have been the first to
come forward to participate in the Feasibility Studies, and
that the introduction of gel in the trial may further facili-
tate condom use in all participants as well as the possibil-
ity that rates in the population might decline with time.
Retention fell below 75% at three of the six locations by
40 weeks, and this supported a concern that adherence to
gel and to scheduled clinic visits might decline with time.
It was decided that the endpoint for the primary analysis
should be at 40 weeks - but to monitor adherence to gel
closely in the trial. At the request of the US Food and Drug
Administration (FDA), all women were continued in the
trial until 52 weeks to obtain longer term safety data.
Following the Feasibility Studies, a Pilot Study was initi-
ated to assess the trial case record forms (CRF), procedures
for pharmacy and informed consent, the database and the
acceptability of the placebo gel. In particular, a procedure
for verifying the accuracy of answers to questions on
adherence and sexual practices in the CRF was assessed.
This involved cross-checking reported product use against
returned applicators and triangulating self-reported gel
use and sexual behaviour data from the CRF with data
from coital diaries and in-depth interviews. Ethical and
regulatory approval for the Pilot Study was obtained in all
sites. The Pilot Study was completed in all sites before
commencing enrolment into the trial. At each stage of the
protocol development there was continuous consultation
with trial sites before the protocol, CRFs and trial proce-
dures were finalised.
Study arms
The MDP301 trial was designed to compare two alterna-
tive concentrations of the PRO 2000/5 gel, 0.5% and 2%,
to a matching placebo. The randomisation was 1:1:1 and
the sample size was calculated to provide adequate power
for the comparison of each of the active gel arms with the
placebo arm. The use of a single placebo arm to evaluate
the efficacy of two alternative products is a more efficient
design than carrying out two separate trials. The rationale
for choosing a low and a high dose of PRO 2000/5 was
that whilst the highest tolerable dose was likely to provide
the greatest biological efficacy against HIV, the possibility
that minor, undetectable, local toxicity could increase the
risk of HIV infection had to be considered.
The possibility of incorporating an additional condom-
only control arm for which no gel is provided was given
consideration, with the rationale that the placebo gel may
provide some protection against infection, diluting any
treatment effect.
The inclusion of a condom-only arm was not included for
three main reasons. First, the placebo being used was thor-
oughly tested and found to have negligible activity against
HIV in vitro, and to afford no protection in a mouse model
for vaginal HSV-2 infection. Second, women in the no gel
arm would not be blind to their treatment allocation. This
could result in a change in their sexual behaviour and con-
dom use, with unpredictable effects on HIV incidence and
any treatment effects. While reported condom use may be
recorded, such data are subject to reporting and recall
bias, which may be differential between study arms, and
it is unlikely that estimated treatment effects could be cor-
rected adequately for behavioural differences. Third,
women in the condom-only control arm may be less
motivated to complete the trial and, if there is higher loss
to follow-up in this arm, this would introduce bias result-
ing in distortion of efficacy estimates.
For these reasons, only a placebo control group was
included in the MDP301 trial. This choice was made rec-
ognising that some dilution of effect due to protection
from the placebo gel could not be ruled out. However,
providing the active gel cannot be identified by partici-
pants, requiring for example that there are no distinguish-
ing adverse or other effects, adequate blinding of study
arms ensures that risk behaviour will be comparable and
that any observed difference in HIV incidence can be con-
fidently ascribed to the active gel.
Study schedule
A summary of the study schedule of visits and procedures
is shown in Figure 2. Women attended an initial screening
visit at which eligibility for the trial was assessed. Only
women who were known to be HIV-negative were
enrolled in the trial, and so the screening visit included
HIV testing and counselling. Women were asked to return
for the randomisation visit up to 6 weeks later and, if they
satisfied all the eligibility criteria and gave informed con-
sent, they were enrolled in the trial.
From the date of enrolment, women are being followed
up for 52 weeks and are seen every 4 weeks for provision
of gel. At each of these visits, sufficient gel is dispensed to
carry them through to the next visit, with a buffer stock in
case of late or missed visits. Women are asked to bring
used and unused gel applicators with them to each
monthly visit, and careful counts are made to ensure full
gel accountability and to allow gel exposure estimates.
At enrolment and at the 4, 12, 24, 40 and 52 week visits,
additional procedures are carried out according to the
schedule. These include a clinical evaluation with genital
examination, and the collection of specimens for the diag-
nosis of HIV, incident herpes simplex type 2 infection
(HSV2), syphilis, Neisseria gonorrhoea (NG),  Chlamydia
trachomatis (CT), Trichomonas vaginalis (TV), bacterial
vaginosis (BV) and candida.Trials 2009, 10:99 http://www.trialsjournal.com/content/10/1/99
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At every follow-up visit, a urine specimen is tested for
pregnancy and all pregnant women are told to interrupt
gel use, but are asked to remain under follow-up. The pro-
tocol was amended to allow women to restart gel use fol-
lowing a negative pregnancy test, normal pelvic
examination and 3 to 6 weeks after termination/early mis-
carriage or delivery respectively. Data are also collected on
outcome of pregnancy.
Routine laboratory parameters for haematology, coagula-
tion tests and biochemistry were collected from the first
500 women enrolled at the Durban and Johannesburg
research clinics, and also (following a request from the
FDA to include a non South African site) all the women
enrolled in Masaka.
At weeks 4, 24, 40 and 52 women are interviewed in more
detail about sexual behaviour and vaginal practices.
In the Masaka clinics only, women are followed for
between 52 and 104 weeks, depending on when they were
randomised, to provide longer-term information on gel
safety.
Randomisation and blinding
A randomisation list for each clinic was created using a
computerised random number generator by an independ-
Summary of visit schedule for MDP301 participants Figure 2
Summary of visit schedule for MDP301 participants.
Enrolment (week 0) 
Eligibility 
Behavioural interview 
Clinical interview 
General and genital examinations 
Pregnancy and  
STI testing 
Gel dispensing 
1st Clinical follow-up (FU) 
visit (week 4) 
Behavioural interview 
Clinical interview 
Genital examinations 
Pregnancy testing 
Gel dispensing 
Gel collection visits  
(weeks 8,16,20,28,32,36
†) 
Behavioural interview 
Pregnancy testing 
Gel dispensing 
Clinical FU visits  
and Final Clinical Visit 
(weeks 12, 24, 40 and 52
†) 
Behavioural interview 
Clinical interview 
Genital examinations 
Pregnancy, HIV and other STI testing* 
Gel dispensing (not final visit) 
†Visits continue for up to a maximum of 104 weeks for Masaka participants; * HIV testing at 
weeks -6, 12, 24, 40, 52; HSV2 testing at weeks 0, 40, 52; Other STI testing at weeks 0, 24 
Screening (week - 6) 
Demographics 
Eligibility 
Behavioural interview 
Pregnancy and 
HIV testing Trials 2009, 10:99 http://www.trialsjournal.com/content/10/1/99
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ent statistician at the MRC Clinical Trials Unit (CTU) in
London, under the supervision of the Trial Statistician,
AJN. Each list contained unique trial numbers matched to
a series of 9 drug product codes, as manufacture of trial
product took place in several batches. The list matching
drug product codes to each of the three trial arms was kept
separately and was available only to these two statisti-
cians, the additional independent statistician who assists
with unblinded data for the Independent Data Monitor-
ing Committee and those responsible for packaging and
labelling at the manufacturing plant.
Each eligible woman providing informed consent was
given a unique trial number selected sequentially from the
trial register held in each clinic. The pharmacist uses this
trial number and drug product codes to dispense the
appropriate allocation using the randomisation list. The
dispensed boxes of gel applicators are labelled with the
trial number identifier.
The link between trial number and drug product codes is
available to the three statisticians referred to above, phar-
macy personnel and the database designer at CTU. No
personnel at the study sites have any access to the ran-
domisation list, and there is no documentation at the sites
that permits unblinding of product allocation. A hard
copy of the list and a password protected database linking
drug product codes to trial numbers is available only to
pharmacy staff.
These procedures ensure that randomisation concealment
is achieved and that the study is fully blinded, including
participants, staff at the study sites, staff at CTU monitor-
ing trial data, and laboratory personnel.
Endpoints
Primary endpoints
The primary efficacy endpoint is the incidence of HIV
infection in participants confirmed to be HIV negative at
enrolment. HIV serological testing is carried out on sera
collected at enrolment and at the 12, 24, 40 and 52 week
clinic visits (and later visits in Masaka), using site-specific
HIV testing algorithms. All suspected HIV seroconversions
are further evaluated by a central reference laboratory
using an algorithm that incorporates DNA PCR performed
on cells from the buffy coat collected at week 0.
One of the unique aspects of HIV prevention trials is that
the primary efficacy endpoint is also a primary safety end-
point because the possibility of increased risk of acquiring
HIV-infection as a consequence of using the gel cannot be
ruled out. In addition to HIV incidence, all deaths and
severe or life-threatening clinical and laboratory events
confirmed on examination or repeat testing will be pri-
mary safety endpoints.
Secondary endpoints
Pre-clinical data suggest that PRO 2000/5 also has activity
against HSV-2, NG and CT. There are no suitable models
for evaluation of activity against TV or BV. In light of the
tests available for these pathogens and their natural his-
tory, it was decided to use sero-incidence of HSV-2, and
cross sectional prevalence of NG and CT, to assess the effi-
cacy of PRO 2000/5 in preventing these secondary end-
points.
Secondary safety endpoints are all systematically solicited
genital adverse events (non-menstrual bleeding, epithelial
disruption, erythema with and without discomfort,
oedema, discomfort), and all clinical and laboratory
adverse events.
Behavioural measurements
Interpretation of the findings of the trial will depend on
having reliable data on various aspects of behaviour. First,
documenting the demographic and behavioural charac-
teristics of the participants is necessary to evaluate the
likely generalisability of the results to women in other
populations. Second, data on usage of gel and condoms is
essential in interpreting the measured effectiveness of the
product. The term efficacy is generally used to denote the
effect of an intervention under perfect conditions, for
example implying 100% adherence and consistently cor-
rect use. In practice, such conditions cannot be achieved
and microbicide trials will actually measure product effec-
tiveness, this term denoting the effect under actual condi-
tions of use. The level of effectiveness experienced in trials
is, however, likely to be greater than that achieved in rou-
tine conditions.
During the trial, women are counselled to use condoms
for all sex acts, but it is recognised that not all women will
achieve consistent condom use. Since correct condom use
is highly protective against HIV infection (and other STIs),
it is important to monitor gel use during sex acts unpro-
tected by condoms and make every effort to optimise this
during the trial.
Intravaginal practices, such as vaginal cleansing, are
known to be highly prevalent in some of the study popu-
lations and these may interfere with any protective effects
of the gel. Although women are counselled not to engage
in these practices at all, and especially not within one
hour prior to applying the gel and for at least one hour
after sex has occurred, it is recognised that they may not
always comply with this guidance. Thus, measurement of
these practices is also important.
Three main approaches are being used during the trial to
record these variables. First, used and unused applicator
returns are recorded and checked against the dispensing
records. Second, structured questionnaires are used atTrials 2009, 10:99 http://www.trialsjournal.com/content/10/1/99
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each clinic visit to record details of use of gel and con-
doms at the last sex act, and at weeks 4, 24, 40 and 52 a
longer questionnaire is used to capture data on additional
sex acts, anal sex and intra-vagingal hygiene practices.
Third, a random sample of at least 100 women at each site
is asked to fill in pictorial diaries recording number of vag-
inal or anal sex acts, gel and condom use during individ-
ual sex acts, and intra-vaginal practices prior to the visits
at weeks 4, 24 and 52. They are also interviewed in-depth
on these same topics within days of the clinic visit and the
results from all these sources are compared and triangu-
lated. Details of these methods are provided else-
where[11].
Ethical considerations
The MDP301 trial is being carried out in accordance with
international good clinical practice (ICH GCP) guide-
lines. Ethical permission to carry out the trial was given by
local university or national research ethics committees in
South Africa, Tanzania, Uganda and Zambia. Two ethics
committees in the UK reviewed the protocol. The protocol
was also reviewed by the national regulatory authorities in
each participating country, as well as the Food and Drug
Administration in the US where gel was manufactured.
The trial commenced in October 2005 and completed
enrolment in August 2008. Four versions of the protocol
were implemented during this period on receipt of the
necessary approvals.
Informed consent
Informed consent was obtained through a two-stage pro-
cedure. Women were initially requested to give consent
for screening and then subsequently, if they were eligible,
for enrolment and randomisation. An interval of one to
six weeks between the screening and enrolment visits
allowed sufficient time for women to consider carefully
whether they wished to take part. On both occasions,
information was given to women about microbicides, the
risks and benefits of taking part, confidentiality and their
right to withdraw at any time, as well as details of the trial
procedures. Information was provided during one-to-one
interviews with the help of written materials and visual
aids, and women were given the opportunity to raise any
questions or concerns. Volunteers were next asked three
questions that could not be answered yes or no to ascer-
tain that they understood (a) that gel might not protect
them from HIV, (b) that condoms do prevent HIV and (c)
that they would have to stop using the gel if they became
pregnant. Following this procedure, if women agreed to
take part they were asked to indicate their consent by sig-
nature or thumbprint. If the woman was illiterate, an
impartial witness of her choice was present to witness the
discussion and her thumbprint consent.
Key points addressed during the informed consent proce-
dure at enrolment were: (a) that the trial is being con-
ducted to find out whether the gels will prevent HIV
infection; (b) that there is a one in three chance that par-
ticipants will receive the placebo gel and that no-one,
including the staff, will know which product she is using;
(c) that women are asked to use the gel during all sex acts
and, because it is not known if the gels are active, that it is
best if condoms are also used whenever possible; (d) that
women will have to be withdrawn from gel if they become
pregnant; (e) that symptoms such as genital irritation,
unexpected bleeding, sores and ulcers should be reported
to the study team regardless of whether the participant
thinks they are related to product use; and (f) that they are
asked to answer questions, especially those regarding gel
use and sexual practices, as accurately as possible.
At specific visits during follow-up each participant's com-
prehension of the following is reviewed: a) that no-one
knows whether any of the study products will protect
against HIV or STI infections and so it is best to use con-
doms with gel; b) that they should contact the study staff
before their next appointment if they have a problem such
as bleeding or suspect that they might be pregnant; c) that
they need to try to answer the questions about gel use
accurately; d) that they are free to withdraw or stop using
gel at any time.
Standard of care
At the 12, 24, 40 and 52 week clinic visits, women are pro-
vided with HIV testing and counselling with promotion of
safer sex practices, provision of free condoms, and diagno-
sis and treatment of sexually transmitted diseases. Women
are advised to use a reliable method of contraception dur-
ing the trial and several are available through the research
clinics. A pregnancy test is carried out at every scheduled
visit to the clinic. Women who become pregnant are with-
drawn from study gel but asked to continue to attend their
clinical follow-up visits, and will be followed up to record
the outcome of pregnancy and included in a secondary
MITT analysis (see below).
Women found to be HIV-positive at screening or who
become HIV seropositive during follow-up are referred to
local services for HIV treatment and care according to pro-
cedures developed at each study site.
Trial oversight
MDP301 has an Independent Data Monitoring Commit-
tee (IDMC) which meets every 4-6 months to review the
data on adverse events and HIV incidence by study arm
and consider any emerging current literature. The IDMC is
responsible for advising the Trial Steering Committee
(TSC) of any changes that it recommends in the conduct
of the study that may be required during the course of the
trial. Because of the unique nature of the trial whereby
HIV-seroconversion is the primary endpoint for both effi-
cacy and safety the IDMC have had access to unblindedTrials 2009, 10:99 http://www.trialsjournal.com/content/10/1/99
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data on seroconversion rates by study arm at all of their
meetings. No formal stopping rules were suggested for
safety concerns. There was one planned efficacy interim
analyses which took place after accumulation of half the
expected woman-years, and the IDMC were to advise the
TSC to stop the trial early in the event of overwhelming
evidence of efficacy (p < 0.001). Adopting this approach
allows for (approximate) preservation of the type I error
rate at the end of the trial[12,13].
Community mechanisms have been established in each
study site to facilitate a two-way flow of information
between the study team and study population and to pro-
vide a forum where any concerns about the trial can be
discussed.
Sample size
At study onset, the proposed primary endpoint was HIV
sero-conversion by the week 40 visit in a participant con-
firmed to be negative at enrolment. The enrolment target
was originally 9673 women, to enable 2055 woman-years
per arm to be accumulated by 40 weeks, allowing for 15%
loss of woman-years due to withdrawals for pregnancy
and loss to follow-up.
As indicated previously we assumed a conservative esti-
mate of HIV incidence in the placebo arm of 4.0 per 100
woman-years. It was considered unrealistic to expect high
efficacy against HIV incidence, and 40% was considered
to be the highest efficacy likely to be achieved. Thus the
power of the study to detect a 40% reduction in incidence
in either of the active gel arms, compared with the placebo
arm, as significant at the 5% level, would be 82%, increas-
ing to 89% if incidence is 5.0 per 100 woman-years. The
study was not powered for a comparison of the two active
gel arms.
Following two protocol amendments described later, the
primary endpoint was moved to week 52 and the sample
size adjusted in order to achieve 80% power at the lower
effect size of 35% reduction in HIV incidence. A revised
estimate of 2640 woman-years per group is now required
in order to achieve this.
Sample size calculations were also carried out for second-
ary and safety endpoints. Data from feasibility and other
studies in the study sites indicated HSV-2 prevalence rang-
ing from 50% to 85%, and HSV-2 incidence of approxi-
mately 10 per 100 woman-years. Assuming that 75% of
the study population is already infected at enrolment and
that HSV-2 incidence is 10 per woman-years then given
approximately 1920 evaluable woman-years of observa-
tion at 52 weeks, the trial would have 90% power to detect
a 50% reduction in HSV-2 incidence or 71% power for a
40% reduction. It is also proposed to compare the preva-
lence of NG and CT infection at the 24 week clinic visit.
Assuming that approximately 7500 women are seen at
this visit, there will be 89% power to detect a reduction in
prevalence of either infection from 6% to 4%, 94% for a
reduction from 3% to 1.5% or 59% power for a reduction
from 3% to 2%. Assuming a minimum of 3000 women
are enrolled in each study arm, there will be considerable
power to detect small increases in rare adverse events, for
example 97% power to detect an increase from 1.5% to
3%, or 80% power to detect an increase from 0.5% to
1.2% or 0.1% to 0.5%.
Modified intention to treat analysis
The primary analysis will be a modified intention to treat
(MITT) analysis in which women will be censored if they
are withdrawn from gel because they become pregnant,
but not if they are withdrawn for other reasons unless they
refuse further follow-up. Following, the protocol amend-
ment to allow women to restart gel following a negative
pregnancy test, the additional woman-years accrued after
re-starting gel will also be included in the MITT analysis.
Intention to treat analysis is usually recommended to pre-
serve the comparability of study arms that is ensured by
randomisation and to avoid selective exclusion of data on
participants who may respond differently to the interven-
tion from those who remain under follow-up throughout.
The justifications for adopting a MITT approach in this
trial are that (a) withdrawal for pregnancy is required by
the study protocol for safety reasons and does not reflect
a participant decision to withdraw which might be related
to experience of the gel; (b) pregnancy rates are not
expected to be influenced by gel use, so that the compara-
bility of study arms ensured by randomisation should be
maintained; and (c) while women are encouraged to use
effective methods of contraception, pregnancy rates in all
study sites remain substantial so that a classical intention
to treat analysis would be expected to considerably under-
estimate product efficacy and thus to reduce the power of
the study.
Closure of 2% study arm
Following a review of the data accrued by 15th January
2008, the IDMC recommended that the 2% gel arm
should be terminated on the grounds of futility, indicat-
ing that continuation of this study arm would be unlikely
to demonstrate significant benefit of this concentration of
PRO 2000/5. This recommendation was accepted by the
TSC, and women remaining on 2% gel at that time were
withdrawn from gel, but asked to continue to attend the
long clinic visits at weeks 4, 12, 24, 40 and 52.
The closure of the 2% arm provided an opportunity to
redirect resources to maximise the precision and power of
the trial for the 0.5% gel vs placebo comparison. It wasTrials 2009, 10:99 http://www.trialsjournal.com/content/10/1/99
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decided to continue with the original enrolment targets,
but with women randomised in a 1:1 ratio to the 0.5%
and placebo arms.
Figure 3 shows the estimated power of the study following
the above design changes, with a 52 week primary end-
point and increased enrolment to the 0.5% and placebo
arms. It shows that the trial will now have 80% power to
detect a lower effect size of 35% assuming a control inci-
dence of 4% (conservative) in the control arm. This
increases to 85% and 88% assuming a control incidence
of 4.5% and 5% respectively.
Timing of primary endpoint
The primary endpoint was initially planned to be HIV
incidence up to 40 weeks follow-up. It was argued that fol-
low-up and adherence to gel use were likely to decrease
over time and that a long duration of follow-up might
therefore compromise the ability of the trial to demon-
strate product efficacy. Given the need for proof of con-
cept that HIV incidence can be reduced by a topical
microbicide, a short follow-up period of 6 months or even
3 months might be adopted to maximise adherence and
thus estimated product efficacy. However, this has to be
weighed against the cost and complexity of enrolling very
large numbers of women in order to accrue sufficient
woman-years of observation with such a short follow-up
period. The choice of 40 weeks follow-up was a compro-
mise designed to ensure adequate adherence and follow-
up without an undue increase in cost and logistical diffi-
culty.
During the course of the trial, after monitoring adherence
and follow-up rates in May 2008, it was clear that the ini-
tial concerns justifying the adoption of a shorter follow-
up were not supported by the data. There was little evi-
dence of fall off in follow-up between weeks 40 and 52,
and all study sites had achieved follow-up of over 80% of
expected participants at the 52 week visit. Moreover,
adherence to gel had remained high with gel use reported
at more than 85% of sex acts throughout follow-up.
Therefore a change of time point for the primary analysis
was considered due to the advantages of longer term fol-
low-up and increased power with the increased woman-
years.
Table 2 illustrates the trade-off between increased woman-
years and potentially reduced adherence (implying a
smaller treatment effect) for a primary endpoint of 52
weeks instead of 40 weeks, assuming HIV incidence in the
placebo arm is 4.0 per 100 woman-years, with efficacy
estimates ranging from 30% to 40% with 80% gel adher-
ence up to 40 weeks. If gel adherence remains at 80%
from 40 to 52 weeks (scenario 1), study power is increased
substantially with a 52 week endpoint, from 85% to 90%
for 40% effect size. Even if adherence falls as low as 50%
from week 40 to week 52 (scenario 2), there is still a slight
increase in study power with the 52 week endpoint (85%
to 86%), and only a small change in the measured efficacy
(37% compared to 40%). In the unlikely worst case sce-
nario of the adherence dropping to 0% (scenario 3) then
the corresponding power drops to 79% (from 85%) and
efficacy measure to 34% (from 40%).
Based on these observations, a proposal was made to
change the primary endpoint to HIV incidence by the
week 52 visit, and this decision was endorsed by the TSC.
This decision was made without disclosure of the accruing
data on HIV incidence in the remaining two study arms.
Discussion
In the era of roll-out of antiretroviral therapy, prevention
of HIV infection has become an even more important pri-
ority since it will be very difficult to sustain adequate treat-
ment services for those who need it unless the number of
new infections can be brought under control. While there
have recently been a number of disappointing results
from trials of vaginal microbicides, the development of
effective microbicide products remains one of the strong-
est hopes for new biomedical prevention tools.
Microbicide trials are large, complex and costly and it is
important that they are designed and conducted carefully
so as to maximise the precision of the results. Adequately
powered trials ensure that the efficacy of an effective prod-
uct can be established. Equally, if the product is ineffec-
Effect on study power when follow-up for primary endpoint  increased from 40 to 52 weeks for different assumptions  concerning adherence and HIV incidence Figure 3
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tive, narrow confidence intervals ensure that such trials
are able to rule out clinically important effects.
A number of special considerations in the design of this
trial have been highlighted in this paper. First, the incor-
poration of two active gel arms, with different concentra-
tions of PRO 2000/5, allows the comparison of each
concentration with placebo more efficiently than in two
independent two-arm studies. However, we decided
against the incorporation of a fourth condom-only con-
trol arm, arguing that observed differences in HIV inci-
dence between this arm and the gel arms would be very
difficult to interpret. This could lead to greater confusion
at the same time as increasing the cost and complexity of
the trial.
Second, we chose to adopt for our primary analysis a
modified intention to treat approach in which observa-
tions on women who become pregnant are censored at
the time they are withdrawn from gel. While a full inten-
tion to treat analysis will also be carried out as a secondary
analysis, we have provided a justification for the modified
approach to be used for our primary analysis.
Third, when there is a pressing need to establish an effec-
tive microbicide as a new biomedical tool, it may be advis-
able to limit the follow-up period so as to maximise
product adherence and minimise losses to follow-up. This
helps to ensure that efficacy is not under-estimated. How-
ever, cost and logistical factors also need to be considered
and a follow-up period that is very short would not be fea-
sible since it would require the screening and enrolment
of extremely large numbers of women. This is of particular
concern in study populations with high HIV prevalence,
since this increases the number of women who have to be
screened to enrol the target number of HIV-negative
women into the trial. We initially adopted a 40 week (9
month) primary endpoint for HIV incidence as a compro-
mise between ensuring high adherence while minimising
cost and sample size. As the trial proceeded, however, we
changed to a 52 week (12 month) primary endpoint after
observing that adherence and follow-up rates remained
high beyond 40 weeks. No operational changes were nec-
essary to implement this into the trial as all women were
already being followed to week 52 for safety as requested
by the FDA.
Fourth, measurement of behaviours such as frequency of
sex acts and use of gel and condoms is very important in
trials of this kind so that efficacy can be estimated from
measured product efficacy, particularly in unprotected sex
acts where condoms are not used. Triangulation of the
behavioural data from a variety of quantitative and quali-
tative methods in this trial, including the use of coital dia-
ries and in-depth interviews, will provide a measure of
how reliable these data are, as well as an understanding of
the factors influencing product use.
Finally, we have taken the opportunity provided by the
premature closure of the 2% gel arm in this trial to redis-
Table 2: Trade-off between increased woman-years (power) and falling adherence.
Scenario Week Adherence Observed reduction
in HIV incidence*
95% CI % power
1. Adherence is unchanged from
Week 40 to week 52
40 80% 40% (17%, 56%) 85%
52 80% 40% (20%, 55%) 90%
40 80% 35% (11%, 52%) 72%
52 80% 35% (14%, 51%) 80%
40 80% 30% (6%, 48%) 55%
52 80% 30% (8%, 47%) 64%
2. Adherence drops to 50% at week 52 40 80% 40% (17%, 56%) 85%
52 50% 37% (16%, 53%) 86%
40 80% 35% (11%, 53%) 72%
52 50% 33% (12%, 49%) 75%
40 80% 30% (6%, 48%) 55%
52 50% 29% (8%, 46%) 66%
3. Adherence drops to 0% at week 52 40 80% 40% (17%, 56%) 85%
52 0% 34% (14%, 50%) 79%
40 80% 35% (11%, 52%) 72%
52 0% 29% (6%, 45%) 63%
40 80% 30% (6%,48%) 55%
52 0% 25% (2%, 42%) 50%
*Compared to placebo
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tribute resources so that precision of our findings on the
0.5% gel is optimised. Based on the observed overall HIV
incidence during the trial, we will have high power of
detecting an effect of clinical significance if this gel is effec-
tive. Increased power at this lower effect size has become
even more relevant in light of the recent results from the
Phase IIb study of 0.5% PRO 2000/5 gel which observed
a 30% reduction in HIV incidence in the PRO 2000/5 gel
arm compared to placebo, p = 0.1[14]. Enrolment to the
MDP301 trial was completed in August 2008, follow-up
will be completed in September 2009 and the results
should be available by the end of 2009.
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Appendix
Description of study populations
1. 6805 women from communities with access to primary
health care facilities in Durban (n = 2391), Johannesburg
(n = 2500) and the Africa Centre sites (n = 1177), South
Africa, and in Mazabuka, Zambia (n = 737)
2. 598 women who were entitled to primary care either
through their employment or their partner's employment
on the Nakambala sugar estate in Mazabuka, Zambia
3. 1146 women working in bars, hotels, guesthouses and
other food or recreational facilities in or near Mwanza
City, northern Tanzania
4. 840 HIV sero-discordant couples (and some sero-con-
cordant negative couples to maintain blinding of sero-sta-
tus) recruited in the Masaka district of Uganda from either
office based voluntary counselling and testing services or
following census and sero-survey
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